The B vitamins have a special place in PD. They are directly linked to motor and cognitive issues and their effectiveness is compromised by the most common medications.
The B-vitamins, including vitamins B12, B6, B1, B2, niacin (B3) and folate (B9), have been implicated as protective risk factors against cognitive decline and Alzheimer’s disease. (Morris 2006) PMID: 16917152
Raised plasma total homocysteine is a strong prognostic marker of future cognitive decline, and is common in world populations. Low-normal concentrations of the B vitamins, the main determinant of homocysteine concentrations, are also common and occur in particularly vulnerable sections of the population, such as infants and elderly. (Smith 2008) PMID: 18709889
Elevated plasma homocysteine (Hcy) concentrations have been reported in L-dopa treated Parkinson’s disease (PD) patients, suggesting that L-dopa treatment is an acquired cause of hyperhomocysteinemia. (Zoccolella 2005) PMID: 15734674
Analysis of data revealed that Hcy levels were higher in L-dopa treated PD patients when compared with age- and sex-matched controls and that supplementation of the diet with cobalamin and folate is effective in reducing Hcy concentrations (Lamberti 2005) PMID: 15804266
Elevated concentration of total homocysteine (Hcy) in plasma (> 12 micromol/l) is a risk factor for several diseases of the central nervous system. Epidemiological studies have shown a dose-dependent relationship between concentrations of Hcy and the risk for neurodegenerative diseases. Hcy is a marker for B-vitamin deficiency (folate, B12, B6). (Herrmann 2007) PMID: 17729191
Vitamin B12 deficiency is an important nutritional disorder causing neurological manifestations of myelopathy, neuropathy and dementia. Sub-acute combined degeneration (SCD) with involvement of the posterior columns in the cervical and thoracic cord is a common presentation of this disorder. (Puntambekkar 2009) PMID: 19720386